Roberts, Andrew W.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 3,058

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 1,047

Programmed Anuclear Cell Death Delimits Platelet Life Span

Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell

Platelet Disorders and TreatmentsCell death mechanisms and regulation

Cited by 1,031

SOCS3 negatively regulates IL-6 signaling in vivo

Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology

Cytokine Signaling Pathways and InteractionsProtein Tyrosine Phosphatases

Cited by 840

Deficiency of the Hematopoietic Cell-Specific Rho Family GTPase Rac2 Is Characterized by Abnormalities in Neutrophil Function and Host Defense

Roberts, A. W., Kim, C., Zhen, L., Lowe, J. B., Kapur, R., Petryniak, B., Spaetti, A., Pollock, J. D., Borneo, J. B., Bradford, G. B., et al. (1999) · Immunity

Neutrophil, Myeloperoxidase and Oxidative MechanismsProtein Kinase Regulation and GTPase Signaling

Cited by 556

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Blombery, P., Anderson, M. A., Gong, J.-N., Thijssen, R., Birkinshaw, R. W., Thompson, E. R., Teh, C. E., Nguyen, T., Xu, Z., Flensburg, C., et al. (2019) · Cancer Discovery

Chronic Lymphocytic Leukemia ResearchCell death mechanisms and regulation

Cited by 434

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery

Cell death mechanisms and regulationAcute Myeloid Leukemia Research

Cited by 432

Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood

Platelet Disorders and TreatmentsBlood Coagulation and Thrombosis Mechanisms

Cited by 351

G-CSF: a key regulator of neutrophil production, but that's not all!

Roberts, A. W. (2005) · Growth Factors

Neutropenia and Cancer InfectionsCytokine Signaling Pathways and Interactions

Cited by 335

Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3

Roberts, A. W., Robb, L., Rakar, S., Hartley, L., Cluse, L., Nicola, N. A., Metcalf, D., Hilton, D. J., & Alexander, W. S. (2001) · Proceedings of the National Academy of Sciences

Cytokine Signaling Pathways and InteractionsReproductive System and Pregnancy

Cited by 300

SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis

Croker, B. A., Metcalf, D., Robb, L., Wei, W., Mifsud, S., DiRago, L., Cluse, L. A., Sutherland, K. D., Hartley, L., Williams, E., et al. (2004) · Immunity

Cytokine Signaling Pathways and InteractionsBlood disorders and treatments

Cited by 285

Suppressor screen in Mpl -/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling

Carpinelli, M. R., Hilton, D. J., Metcalf, D., Antonchuk, J. L., Hyland, C. D., Mifsud, S. L., Di Rago, L., Hilton, A. A., Willson, T. A., Roberts, A. W., et al. (2004) · Proceedings of the National Academy of Sciences

Platelet Disorders and TreatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment

Cited by 179

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., Hallek, M., Byrd, J. C., Humphrey, K., Zhou, L., et al. (2019) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 178

A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer

Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 148

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Blombery, P., Thompson, E. R., Lew, T. E., Tiong, I. S., Bennett, R., Cheah, C. Y., Lewis, K. L., Handunnetti, S. M., Tang, C. P. S., Roberts, A., et al. (2022) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 91

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

Flinsenberg, T. W. H., Tromedjo, C. C., Hu, N., Liu, Y., Guo, Y., Thia, K. Y. T., Noori, T., Song, X., Aw Yeang, H. X., Tantalo, D. G., et al. (2020) · Haematologica

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 56